241 related articles for article (PubMed ID: 28473136)
41. Double-blind efficacy and safety study of a novel anti-ischemic agent, ranolazine, versus placebo in patients with chronic stable angina pectoris. Ranolazine Study Group.
Thadani U; Ezekowitz M; Fenney L; Chiang YK
Circulation; 1994 Aug; 90(2):726-34. PubMed ID: 8044941
[TBL] [Abstract][Full Text] [Related]
42. Impact of treatment strategies on outcomes in patients with stable coronary artery disease and type 2 diabetes mellitus according to presenting angina severity: A pooled analysis of three federally-funded randomized trials.
Mancini GBJ; Boden WE; Brooks MM; Vlachos H; Chaitman BR; Frye R; Bittner V; Hartigan PM; Dagenais GR
Atherosclerosis; 2018 Oct; 277():186-194. PubMed ID: 29861270
[TBL] [Abstract][Full Text] [Related]
43. Patient Characteristics Associated With Antianginal Medication Escalation and De-Escalation Following Chronic Total Occlusion Percutaneous Coronary Intervention.
Hirai T; Qintar M; Grantham JA; Sapontis J; Cohen DJ; Lombardi W; Karmpaliotis D; Moses J; Nicholson WJ; Nugent K; Gosch KL; Spertus JA; Salisbury AC
Circ Cardiovasc Qual Outcomes; 2019 Jun; 12(6):e005287. PubMed ID: 31185735
[TBL] [Abstract][Full Text] [Related]
44. Anti-ischemic and pleiotropic effects of ranolazine in chronic coronary syndromes.
Manolis A; Kallistratos M; Poulimenos L; Thomopoulos C
Am J Med Sci; 2024 Mar; 367(3):155-159. PubMed ID: 38072070
[TBL] [Abstract][Full Text] [Related]
45. Comparison of ranolazine and trimetazidine on glycemic status in diabetic patients with coronary artery disease - a randomized controlled trial.
Sandhiya S; Dkhar SA; Pillai AA; George M; Jayaraman B; Chandrasekaran A
J Clin Diagn Res; 2015 Jan; 9(1):OC01-5. PubMed ID: 25738014
[TBL] [Abstract][Full Text] [Related]
46. Ranolazine: a review of its use in chronic stable angina pectoris.
Keating GM
Drugs; 2008; 68(17):2483-503. PubMed ID: 19016575
[TBL] [Abstract][Full Text] [Related]
47. Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block - a case report.
Yuriivna Osovska N; Vitaliivna Kuzminova N
Pol Merkur Lekarski; 2016 Dec; 41(246):287-292. PubMed ID: 28024133
[TBL] [Abstract][Full Text] [Related]
48. New Anti-Anginal Drugs: Ranolazine.
Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
[TBL] [Abstract][Full Text] [Related]
49. Impact of ranolazine on coronary microvascular dysfunction (MICRO) study.
Ahmed B; Mondragon J; Sheldon M; Clegg S
Cardiovasc Revasc Med; 2017 Sep; 18(6):431-435. PubMed ID: 28576663
[TBL] [Abstract][Full Text] [Related]
50. Impact of ranolazine on clinical outcomes and healthcare resource utilization in patients with refractory angina pectoris.
Ling H; Packard KA; Burns TL; Hilleman DE
Am J Cardiovasc Drugs; 2013 Dec; 13(6):407-12. PubMed ID: 23873327
[TBL] [Abstract][Full Text] [Related]
51. Baseline plasma fibrinogen is associated with haemoglobin A1c and 2-year major adverse cardiovascular events following percutaneous coronary intervention in patients with acute coronary syndrome: a single-centre, prospective cohort study.
Zhang L; Xu C; Liu J; Bai X; Li R; Wang L; Zhou J; Wu Y; Yuan Z
Cardiovasc Diabetol; 2019 Apr; 18(1):52. PubMed ID: 31014348
[TBL] [Abstract][Full Text] [Related]
52. Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain.
Hidalgo-Vega A; Ramos-Goñi JM; Villoro R
Eur J Health Econ; 2014 Dec; 15(9):917-25. PubMed ID: 24122303
[TBL] [Abstract][Full Text] [Related]
53. Influence of revascularization on long-term outcome in patients > or =75 years of age with diabetes mellitus and angina pectoris.
Jeger RV; Bonetti PO; Zellweger MJ; Tobler D; Kaiser CA; Osswald S; Buser PT; Pfisterer ME
Am J Cardiol; 2005 Jul; 96(2):193-8. PubMed ID: 16018840
[TBL] [Abstract][Full Text] [Related]
54. Frequency, predictors, and consequences of crossing over to revascularization within 12 months of randomization to optimal medical therapy in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial.
Spertus JA; Maron DJ; Cohen DJ; Kolm P; Hartigan P; Weintraub WS; Berman DS; Teo KK; Shaw LJ; Sedlis SP; Knudtson M; Aslan M; Dada M; Boden WE; Mancini GB;
Circ Cardiovasc Qual Outcomes; 2013 Jul; 6(4):409-18. PubMed ID: 23838107
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of glucose metabolism for non-ST-segment elevation infarction patients with diabetes mellitus and single concomitant chronic total occlusion following primary percutaneous coronary intervention.
Xing Z; Zhang L; Liu Z; He P; Yang Y; Wulasihan M
Medicine (Baltimore); 2017 Nov; 96(45):e8362. PubMed ID: 29137017
[TBL] [Abstract][Full Text] [Related]
56. Pharmacological Management of Chronic Stable Angina: Focus on Ranolazine.
Rosano GMC; Vitale C; Volterrani M
Cardiovasc Drugs Ther; 2016 Aug; 30(4):393-398. PubMed ID: 27417323
[TBL] [Abstract][Full Text] [Related]
57. The evolving role of medical therapy for chronic stable angina.
Eid F; Boden WE
Curr Cardiol Rep; 2008 Jul; 10(4):263-71. PubMed ID: 18611360
[TBL] [Abstract][Full Text] [Related]
58. Effects of ranolazine on disease-specific health status and quality of life among patients with acute coronary syndromes: results from the MERLIN-TIMI 36 randomized trial.
Arnold SV; Morrow DA; Wang K; Lei Y; Mahoney EM; Scirica BM; Braunwald E; Cohen DJ;
Circ Cardiovasc Qual Outcomes; 2008 Nov; 1(2):107-15. PubMed ID: 20031797
[TBL] [Abstract][Full Text] [Related]
59. Association between Ranolazine, Ischemic Preconditioning, and Cardioprotection in Patients Undergoing Scheduled Percutaneous Coronary Intervention.
Kourtis K; Bourazana A; Xanthopoulos A; Skoularigkis S; Papadakis E; Patsilinakos S; Skoularigis J
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38256425
[No Abstract] [Full Text] [Related]
60. Glycemic Control Status After Percutaneous Coronary Intervention and Long-Term Clinical Outcomes in Patients With Type 2 Diabetes Mellitus.
Hwang JK; Lee SH; Song YB; Ahn J; Carriere K; Jang MJ; Park TK; Choi SH; Yang JH; Choi JH; Lee SH; Gwon HC; Hahn JY
Circ Cardiovasc Interv; 2017 Apr; 10(4):. PubMed ID: 28373177
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
